



7 Lightweight social distancing recommended. Protect vulnerable residents. Wear masks in crowded areas. Avoid very large group gatherings. Continue active testing and contact tracing.



Positive Factors

108 days since peak contagiousness; Low positive testing percent (2.8%) (major factor); Low population density (17 per sq mile); Estimated 30% decrease in 14-day fatality rate (major factor).

Key Indicator

Rating


Metric

| | | |
|--------------------------|---|---------------------------------------|
| Contagious Cases | ✓ | 2.4 per 1000 residents |
| Contagiousness Trend | ✓ | 42% of peak |
| Trend Steadiness | ✓ | 108 days since peak |
| Test Completeness | ✓ | 2.8% positive tests |
| Population Density | ✓ | 17 per sq mile |
| 14-Day Fatality Forecast | ✓ | 30% decrease in 14-day fatality rate |
| Disease Control | ✓ | Infections 300% of day of first death |
| Population Resistance | ✓ | 6% residents with antibodies |
| Population Vulnerability | ✓ | IFR is 1.05x North American |


Negative Factors

225% more contagious cases now than on the day of the first death; Not enough residents with antibodies (6%).


Actively Contagious Cases in New Mexico




Risk to Different Population Groups



| Contagiousness | Minimum | Probable | Possible |
|--|------------|------------|------------|
| Contagious cases today | 4,500 | 5,000 | 5,500 |
| Per 1,000 residents | 2.2 | 2.4 | 2.7 |
| Contagious residents, ratio | One in 450 | One in 400 | One in 400 |
| Peak number of contagious cases (5/1/20) | | 12,000 | |




| Fatalities | Last 7 Days | Last 14 Days | All Time |
|----------------------------------|---------------|---------------|--------------|
| Days since first death (3/25/20) | | | 145 |
| Smoothed number of deaths | 29 | 60 | 714 |
| Per 1,000 residents | 0.01 | 0.03 | 0.34 |
| Ratio, per resident | One in 72,500 | One in 35,000 | One in 3,000 |




| Trends in Testing | Last 7 Days | Last 14 Days | All Time |
|--|--------------|---------------|-----------|
| Days since first positive test (3/11/20) | | | 159 |
| Smoothed number of positive tests | 1,136 | 2,455 | 23,432 |
| Per 1,000 residents | 0.54 | 1.17 | 11.17 |
| Ratio, per resident | One in 1,800 | One in 900 | One in 90 |
| Trend | -183 (-14%) | -1,541 (-39%) | - |

| Trends in Fatality | Last 7 Days | Last 14 Days | All Time |
|--------------------------------|--------------------------------------|--------------|----------|
| Trend, Past | -2 (-6%) | -19 (-24%) | - |
| Predicted Deaths, Next 14 Days | 35 | 40 | 60 |
| Per 1,000 residents | 0.02 | 0.02 | 0.03 |
| Overall Trend, Next 14 Days | 30% decrease in 14-day fatality rate | | |


| Infections | Minimum | Probable | Possible |
|------------------------------------|---------|----------|----------|
| Infections-to-date, % of residents | 5.8% | 6.3% | 6.8% |




Immunity



| Positive Test Percentage | Last 7 Days | Last 14 Days | All Time |
|----------------------------------|-------------|--------------|----------|
| Positive tests as % of all tests | 3.2% | 2.8% | 3.5% |



New Mexico Raw Data



Covid-19 Open Readiness Assessment Notes




Report Date: 08/17/20
Assessment Model Version 1.22

Data Sources. State level data for the daily numbers and total numbers of positive tests, negative tests, total tests, and deaths has been retrieved from the Covid Tracking Project. The Covid Tracking Project data comes from individual state websites. Selected data has been retrieved directly from individual state websites, especially data for the state of New York. Demographic data has been retrieved from the US Census Bureau. Geographic data has been retrieved from Wikipedia. Canadian data is from the Government of Canada.


Common Issues with State-Level Data. Many states' raw data contains irregularities, including individual days with spikes in the number of deaths, positive tests, or negative tests; days in which less than zero results are reported (i.e., correcting earlier over-reporting by reporting negative numbers on a single day); and days in which data is missing completely. Some states in May 2020 mingled antibody testing data with virus testing data, and then later corrected the data by making large adjustments on one day. Data for states with low numbers of deaths or relatively small populations will appear more irregular than larger states.

Data Smoothing. Many states do not report results daily. Many states show weekly cycles of under-reporting on certain days and over-reporting on other days. Consequently, test data and fatality data is smoothed to include a 7-day cycle. Smoothing periods shorter than 7 days or longer than 7 days risk disproportionately weighting the days on which results are underreported or overreported.


Test Cases. Positive test cases are used as a basis for calculating the total number of infections, as well as for trending the number of infections. The graph below shows the number of positive test per 1,000 residents in each state. States are arranged from west-to-east to help show regional trends.



Positive Test Percentage/State Testing Effectiveness. The percentage of virus tests that show positive results ("positivity") is an indicator of what percentage of the total infections is being identified through testing. The higher the positivity is, the lower the percentage of overall infections being detected is. Most states started with high positivity (in some cases 30-40%) and are now down to 2.5-10% positivity. The graph below shows the positivity of each state's tests over the past 14 days.



The level of positivity implies that the actual number of infections in each state is 7-10 times as high as the number of positive tests. The graph below shows the percentage of infections that each state's tests have identified over the past 14 days.




Total number of infections. Test cases account for only a fraction of total infections, due to many people being asymptomatic and not seeking testing, limited test availability early in the pandemic, state strategies of testing only high risk individuals, and other factors. Total infections are estimated in two ways.

Infection Model 1 estimates infections based on the number of deaths 14 days after the date of the infection report (the day most test results are reported that later result in those deaths). Infections are calculated as the number of people who would have needed to be infected as of that particular test date to produce the number of actual deaths 14 days later.

Infection Model 2 estimates infections based on the percentage of test results that are positive in each state combined with average age being tested nationally. This calculation is based on a curve-fitted model derived both from longitudinal state-level data and from daily test and death data, using the 14 day lag between tests and deaths.


Total Population Infected Over Time. These infection models can be used to estimate the total number of people in each state that have been infected since the beginning of the pandemic. The graph below shows an estimate of the estimated percentage of people in each state who have been infected.



Cases as of Day of First Death. Many states had extensive infections as of the day of the first Covid-19 death in the state. Comparing the current level of contagiousness to the level on the day of the first death allows for comparison of justification for social distancing then and now.

The graph below shows the approximate number of infections in each state on the day of the first death. This is calculated based on the number of infections needed on the day of the first death to produce the number of deaths actually observed 18 days later.

The number of infections varies significantly. New York had about a half million infections as of the day of the first death that it needed to address. California, with twice the population of New York, had only a tiny fraction of that number to address.




Contagiousness period. The contagious period is treated as the 9-day period from 2 days before a positive test result to 6 days after.

Actively Contagious Cases. Current contagiousness is compared to peak contagiousness and contagiousness as of the day of first death. Comparison to peak contagiousness indicates the degree to which the state has controlled covid-19.


IFR baseline. A baseline Infection Fatality Rate (IFR) is calculated using New York state's antibody study. Based on antibody tests conducted the weekend of April 18-19, 2.71 million residents in New York were determined to have been infected. Two timing considerations were included: (1) After 21 days 95% of infected patients test positive for antibodies; (2) Average time from infection to death is 18 days. Using total deaths from April 16 yields a New York-specific IFR of 0.500%. The New York-specific IFR was divided by a demographic adjustment factor of 0.984 to produce a Baseline IFR for the US of 0.508%. Details can be found here.

State-Level IFRs. Each state is assigned a state-level IFR based on specific age distribution of its population. The ratios of the states' IFRs to the US-average IFR are shown in the graph below.



Scoring Criteria. Scoring is a combination of weighted factors and rules-based scoring. Criteria are weighted as follows: contagious cases (30%), test completeness (20%), fatality forecast (15%), contagiousness trend (10%), trend steadiness (10%), population density (7.5%), long-term change (2.5%), population resistance (2.5%), population vulnerability (2.5%). Very high contagiousness and/or significant irregularities in state-reported data limit the maximum score a state can receive; very low contagiousness can further improve a state's score.

Estimated Deaths. Deaths for the 14-day period following testing can be estimated fairly accurately using the number of positive test cases, recent CFR (rather than IFR), and positive test percentage. Using this approach, this is the estimate for total deaths in the US over the next 14 days.



About the Author



Steve McConnell has been a leading expert in software estimation, software measurement, and software engineering practices for more than 20 years. In this assessment, Steve has used his expertise in data analysis, measurement, and forecasting to analyze and forecast Covid-19 data. Steve is best known as the author of the software industry classics *Code Complete* and *Software Estimation: Demystifying the Black Art*.

Steve's company, Construx Software, provides training for high potential software development teams and consulting support for companies committed to being world-class software organizations. The performance measurement system used in this assessment is similar to performance management systems that Construx staff have implemented in leading companies worldwide. Steve welcomes your contact through the channels below.



stevemcc@construx.com



LinkedIn.com/in/stevemcc